Alkermes shares promoted to “Buy” by UBS analyst
In view of the fact that Alkermes Inc. experienced a decline in stock prices over the last month, the company’s
Read morealkermes
FDA approval for Lilly’s Bydureon delayed until Jan 28
Subsequent to a delay of one year for the approval of once-per-week diabetes drug Bydureon, the United States Food and
Read more